Article information
Full text is only aviable in PDF
Bibliografía
[1.]
G.J. Rodrigo, V. Plaza, J. Bellido-Casado, H. Neffen, M.T. Bazús, G. Levy, et al.
Changes in the characteristics of patients hospitalized for acute asthma over a ten-year period (1994–2004) in Spain and Latin-America: the Eagle study.
Brazilian J Pulmonology, 35 (2009), pp. 635-644
[2.]
G.J. Rodrigo.
¿Están verdaderamente basadas en la evidencia las guías sobre el asma? Un análisis crítico.
Arch Bronconeumol, 44 (2008), pp. 81-86
[3.]
G.J. Rodrigo, C. Rodrigo, J.B. Hall.
Acute asthma in adults. A review.
Chest, 125 (2004), pp. 1081-1102
[4.]
M. Chan-Yeung, J.H. Chang, J. Manfreda, A. Ferguson, A. Becker.
Changes in peak flow, symptom score, and the use of medications during acute exacerbations of asthma.
Am J Respir Crit Care Med, 156 (1996), pp. 889-893
[5.]
A.E. Tattersfield, D.S. Postma, P.J. Barnes, K. Svensson, C.A. Bauer, P.M. O’Byrne, et al.
Exacerbations of asthma: a descriptive study of 425 severe exacerbations.
Am J Respir Crit Care Med, 160 (1999), pp. 594-599
[6.]
E.M. Martínez-Moragón, A. Perpiñá, A. Belloch, A. De Diego, M.E. Martínez-Francés.
Percepción de la disnea durante la broncoconstricción aguda en los pacientes con asma.
Arch Bronconeumol, 39 (2003), pp. 67-73
[7.]
R. Magadle, N. Berar-Yanay, P. Weiner.
The risk of hospitalization and near-fatal and fatal asthma in relation to the perception of dyspnea.
Chest, 121 (2002), pp. 329-333
[8.]
M.O. Turner, K. Noertjojo, S. Vedal, T. Bai, S. Crump, J.M. Fitzgerald.
Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma.
Am J Respir Crit Care Med, 157 (1998), pp. 1804-1809
[9.]
V. Plaza, J. Serrano, C. Picado, J. Sanchis.
Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma.
Eur Respir J, 19 (2002), pp. 846-852
[10.]
J.M. Antó, J.M. Sunyer.
Epidemic asthma.
Difficult asthma, pp. 333-340
[11.]
P.G. Woodruff, S.D. Edmond, A.K. Singh, C.A. Camargo.
Sudden-onset acute asthma: clinical features and response to therapy.
Acad Emerg Med, 5 (1998), pp. 695-701
[12.]
G. Rodrigo, C. Rodrigo.
Rapid-onset attack: a prospective study cohort about characteristics and response to emergency department treatment.
Chest, 118 (2000), pp. 1547-1552
[14.]
I. Otero González, M. Blanco Aparicio, C. Montero Martínez, P. Valiño López, H. Verea Hernando.
Características epidemiológicas de las exacerbaciones por EPOC y asma en un hospital general.
Arch Bronconeumol, 38 (2002), pp. 256-262
[15.]
S. Gartner, N. Cobos, E. Pérez Yarza, A. Moreno, S. Liñán, C. De Frutos.
Estudio comparativo de la eficacia de deflazacor frente a prednisolona en el tratamiento de la crisis asmática moderada.
An Pediatr (Barc), 61 (2004), pp. 207-212
[16.]
F. Morell, T. Genover, E. Benaque, C. Picado, X. Muñoz, M.J. Cruz.
Incidencia y características de las agudizaciones asmáticas en Barcelona (ASMABII).
Arch Bronconeumol, 45 (2009), pp. 550-555
[17.]
D.M. Mannino, D.M. Homa, L.J. Akinbami, J.E. Moorman, C. Gwynn, S.C. Redd.
Surveillance for asthma. United States, 1980–1999.
MMWR CDC Surveill Summ, 51 (2002), pp. 1-13
[18.]
D.H. Smith, D.C. Malone, K.A. Lawson, L.J. Okamoto, C. Battista, W.B. Saunders.
A national estimate of the economic costs of asthma.
Am J Respir Crit Care Med, 156 (1997), pp. 787-793
[19.]
J. Serra-Batlles, V. Plaza, E. Morejon, A. Comella, J. Brugues.
Costs of asthma according to the degree of severity.
Eur Respir J, 12 (1998), pp. 1322-1326
[20.]
K.B. Weiss, S.D. Sullivan, C.S. Lyttle.
Trends in the cost of illness for asthma in the United States 1985–1994.
J Allergy Clin Immunol, 106 (2000), pp. 493-499
[21.]
L. Borderías Clau, M. Zabaleta Murguionda, J.A. Riesco Miranda, C. Pellicer Ciscar, J.R. Hernandez Hernandez, T. Carrillo Días, et al.
Arch Bronconeumol, 41 (2005), pp. 313-321
[22.]
D. Getahun, K. Demissie, G.G. Rhoads.
Recent trends in asthma hospitalization and mortality in the United States.
J Asthma, 42 (2005), pp. 373-378
[23.]
V. Plaza, J. Serra-Batlles, E. Morejón, A. Comella, J. Brugués.
Características clínicas y morbilidad en el asma estable. Análisis descriptivo del asma en una comunidad mediterránea.
Arch Bronconeumol, 33 (1997), pp. 457-461
[24.]
I. Cerveri, F. Locatelli, M.C. Zoia, A. Corsico, S. Accordini, R. De Marco.
International variations in asthma treatment compliance.
Eur Respir J, 14 (1999), pp. 288-294
[25.]
R. Louis, L.C.K. Lau, A.O. Bron, A.C. Roldaan, M. Radermecker, R. Djukanovic.
The relationship between airways inflammation and asthma severity.
Am J Respir Crit Care Med, 161 (2000), pp. 9-16
[26.]
S. Suissa, P. Ernst.
Inhaled corticosteroids: impact on asthma morbidity and mortality.
J Allergy Clin Immunol, 107 (2001), pp. 937-944
[27.]
I. Mitchell, S.C. Tough, L.K. Semple, F.H. Green, P.A. Hessel.
Near-fatal asthma: a population-based study of risk factors.
Chest, 121 (2002), pp. 1407-1413
[28.]
A.F. Gelb, A. Schein, E. Nussbaum, C.M. Shinar, Y. Aelony, H. Aharonian, et al.
Risk factors for near-fatal asthma.
Chest, 126 (2004), pp. 1138-1146
[29.]
V. Plaza, J. Serra-Batlles, A. Comella, C. Badiola.
Differences in asthma clinical outcomes according to the initial severity.
J Asthma, 42 (2005), pp. 207-211
[30.]
E.M. Skobeloff, W.H. Spivey, S.S. St Clair, J.M. Schoffstall.
The influence of age and sex on asthma admissions.
JAMA, 268 (1992), pp. 3437-3440
[31.]
E. Martínez-Moragón, V. Plaza, J. Serrano, C. Picado, J.B. Gáldiz, A. López-Viña, et al.
Near-fatal asthma related to menstruation.
J Allergy Clin Immunol, 113 (2004), pp. 242-244
[32.]
C.S. Murray, A. Simpson, A. Custovic.
Allergens, viruses and asthma exacerbations.
Proc Am Thorac Soc, 1 (2004), pp. 99-104
[33.]
R.E. Dales, S. Cakmak, S. Judek, T. Dann, F. Coates, J.R. Brook, et al.
Influence of outdoor aeroallergens on hospitalization for asthma in Canada.
J Allergy Clin Immunol, 113 (2004), pp. 303-306
[34.]
S. Hales, S. Lewis, T. Slater, J. Crane, N. Pearce.
Prevalence of asthma symptoms in relation to climate in New Zealand.
Environ Health Perspect, 106 (1998), pp. 607-610
[35.]
N.W. Johnston, M.R. Sears.
Asthma exacerbations. Epidemiology.
Thorax, 61 (2006), pp. 722-728
[36.]
D.R. Taylor, E.D. Bateman, L.P. Boulet, H.A. Boushey, W.W. Busse, T.B. Casale, et al.
A new perspective on concepts of asthma severity and control.
Eur Respir J, 32 (2008), pp. 545-554
[37.]
P.G. Gibson, H. Powell, F.M. Ducharme.
Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations.
J Allergy Clin Immunol, 119 (2007), pp. 344-350
[38.]
E.F. Juniper, P.M. O’Byrne, P.J. Ferrie, D.R. King, J.N. Roberts.
Measuring asthma control. Clinic questionnaire or daily diary?.
Am J Respir Crit Care Med, 162 (2000), pp. 1330-1334
[39.]
E.F. Juniper, P.M. O’Byrne, G.H. Guyatt, P.J. Ferrie, D.R. King.
Development and validation of a questionnaire to measure asthma control.
Eur Respir J, 14 (1999), pp. 902-907
[40.]
E.F. Juniper, K. Sevensson, A.C. Mörk, E. Stähl.
Measurement properties and interpretation of three shortened versions of the asthma control questionnaire.
Respir Med, 99 (2005), pp. 553-558
[41.]
R.A. Nathan, C.A. Sorkness, M. Kosinski, M. Schatz, J.T. Lim, P. Marcus, et al.
Development of the asthma control test: a survey for assessing asthma control.
J Allergy Clin Immunol, 113 (2004), pp. 59-65
[42.]
M. Schatz, C.A. Sorkness, J.T. Li, P. Marcus, J.J. Murray, R.A. Nathan, et al.
Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists.
J Allergy Clin Immunol, 117 (2006), pp. 549-556
[43.]
J.M. Vega, X. Badia, C. Badiola, A. López-Vinia, J.M. Olaguibel, C. Picado, et al.
Validation of the Spanish version of the Asthma Control Test (ACT).
J Asthma, 44 (2007), pp. 867-872
[44.]
G.J. Rodrigo, J.P. Arcos, L.J. Nannini, H. Neffen, M. González Broin, M. Contrera, et al.
Reliability and factor analysis of the Spanish version of the Asthma Control Test.
Ann Allergy Asthma Immunol, 100 (2008), pp. 17-22
[45.]
P.P. Katz, E.H. Yelin, M.D. Eisner, P.D. Blanc.
Perceived control of asthma and quality of life among adults with asthma.
Ann Allergy Asthma Immunol, 89 (2002), pp. 251-258
[46.]
C.S. Calfee, P.P. Katz, E.H. Yelin, C. Iribarren, M.D. Eisner.
The influence of perceived control of asthma on health outcomes.
Chest, 130 (2006), pp. 1312-1318
[47.]
L. Laforest, E. Van Ganse, G. Devouassoux, L.M. Osman, K. Brice, J. Massol, et al.
Asthmatic patients’ poor awareness of inadequate disease control: a pharmacy-based survey.
Ann Allergy Asthma Immunol, 98 (2007), pp. 146-152
[48.]
P.L. Brand, E.J. Duiverman, H.J. Waalkens, E.E. Van Essen-Zandvliet, K.F. Kerrebijn.
Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long term treatment with inhaled corticosteroids.
Thorax, 54 (1999), pp. 103-107
[49.]
H.K. Reddel, G.B. Marks, C.R. Jenkins.
When can personal best peak flow be determined for asthma action plans?.
Thorax, 59 (2004), pp. 922-924
[50.]
K.J. Killian, R. Watson, J. Otis, T.A. St Amand, P.M. O’Byrne.
Symptom perception during acute bronchoconstriction.
Am J Respir Crit Care Med, 162 (2000), pp. 490-496
[51.]
J.K. Sont, L.N. Willems, E.H. Bel, J.H. Van Krieken, J.P. Vandenbroucke, P.J. Sterk.
Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment.
Am J Respir Crit Care Med, 159 (1999), pp. 1043-1051
[52.]
M.M. Pizzichini, T.A. Popov, A. Efthimiadis, P. Hussack, S. Evans, E. Pizzichini, et al.
Spontaneous and induced sputum to measure indices of airway inflammation in asthma.
Am J Respir Crit Care Med, 154 (1996), pp. 866-869
[53.]
R.H. Green, C.E. Brightling, S. McKenna, B. Hargadon, D. Parker, P. Brading, et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
Lancet, 360 (2002), pp. 1715-1721
[54.]
A. Jatakanon, S. Kharitonov, S. Lim, P.J. Barnes.
Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma.
Thorax, 54 (1999), pp. 108-114
[55.]
P.E. Silkoff, P. McClean, M. Spino, L. Erlich, A.S. Slutsky, N. Zamel.
Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients.
Chest, 119 (2001), pp. 1322-1328
[56.]
A.D. Smith, J.O. Cowan, K.P. Brassett, G.P. Herbison, D.R. Taylor.
Use of exhaled nitric oxide measurements to guide treatment in chronic asthma.
N Engl J Med, 352 (2005), pp. 2163-2173
[57.]
S.I. Jones, J. Kittelson, J.O. Cowan, E.M. Flannery, R.J. Hancox, C.R. McLachlan, et al.
The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control.
Am J Respir Crit Care Med, 164 (2001), pp. 738-743
[58.]
J.M. Sippel, W.E. Holden, S.A. Tilles, M. O’Hollaren, J. Cook, N. Thukkani, et al.
Exhaled nitric oxide levels correlate with measures of disease control in asthma.
J Allergy Clin Immunol, 106 (2000), pp. 645-650
[59.]
A.F. Gelb, C.F. Taylor, C.M. Shinar, C. Gutiérrez, N. Zamel.
Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics.
Chest, 129 (2006), pp. 1492-1499
[60.]
E. Paraskakis, C. Brindicci, L. Fleming, R. Krol, S.A. Kharitonov, N.M. Wilson, et al.
Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma.
Am J Respir Crit Care Med, 174 (2006), pp. 260-267
[61.]
H.L. Petsky, C.J. Cates, A.M. Li, J.A. Kynaston, C. Turner, A.B. Chang.
Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults.
Cochrane Database Syst Rev, (2008),
[62.]
A.D. Smith, J.O. Cowan, S. Filsell, C. McLachlan, G. Monti-Sheehan, P. Jackson, et al.
Diagnosing asthma. Comparisons between exhaled nitric oxide measurements and conventional tests.
Am J Respir Crit Care Med, 169 (2004), pp. 473-478
[63.]
S.A. Kharitonov, P.J. Barnes.
Exhaled markers of pulmonary disease.
Am J Respir Crit Care Med, 163 (2001), pp. 1693-1722
[64.]
L.P. Boulet, V. Boulet, J. Milot.
How should we quantify asthma control? A proposal.
Chest, 122 (2002), pp. 2217-2223
[65.]
J.M. FitzGerald, P.G. Gibson.
Asthma exacerbations. 4: Prevention.
Thorax, 61 (2006), pp. 992-999
[66.]
R.A. Pauwels, S. Pedersen, W.W. Busse, W.C. Tan, Y.Z. Chen, S.V. Ohlsson, et al.
Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial.
Lancet, 361 (2003), pp. 1071-1076
[67.]
A. Woolcock, B. Lundback, N. Ringdal, L.A. Jacques.
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.
Am J Respir Crit Care Med, 153 (1996), pp. 1481-1488
[68.]
R.A. Pauwels, C.G. Lofdahl, D.S. Postma, A.E. Tattersfield, P. O’Byrne, P.J. Barnes, et al.
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol And Corticosteroids Establishing Therapy (FACET) International Study Group.
N Engl J Med, 337 (1997), pp. 1405-1411
[69.]
E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J. Clark, R.A. Pauwels, et al.
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study.
Am J Respir Crit Care Med, 170 (2004), pp. 836-844
[70.]
M. Masoli, M. Weatherall, S. Holt, R. Beasley.
Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.
Thorax, 60 (2005), pp. 730-734
[71.]
S.W. Stoloff, D.A. Stempel, J. Meyer, R.H. Stanford, J.R. Carranza Rosenzweig.
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
J Allergy Clin Immunol, 113 (2004), pp. 245-251
[72.]
P.M. O’Byrne, E. Adelroth.
Beta2 déjà vu.
Chest, 129 (2006), pp. 3-5
[73.]
M.J. Vaquerizo, P. Casan, J. Castillo, M. Perpiñá, J. Sanchis, V. Sobradillo, et al.
Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma.
Thorax, 58 (2003), pp. 204-210
[74.]
H. Milgrom, R.B. Fick, J.Q. Su, J.D. Reimann, R.K. Bush, M.L. Watrous, et al.
Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
N Engl J Med, 341 (1999), pp. 1966-1973
[75.]
M. Soler, J. Matz, R. Townley, R. Buhl, J. O’Brien, H. Fox, et al.
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
Eur Respir J, 18 (2001), pp. 254-261
[76.]
H.A. Boushey, C.A. Sorkness, T.S. King, S.D. Sullivan, J.V. Fahy, S.C. Lazarus, et al.
Daily versus as-needed corticosteroids for mild persistent asthma.
N Engl J Med, 352 (2005), pp. 1519-1528
[77.]
A. Papi, G.W. Canonica, P. Maestrelli, P. Paggiaro, D. Olivieri, E. Pozzi, et al.
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma.
N Engl J Med, 356 (2007), pp. 2040-2052
[78.]
P.M. O’Byrne, H. Bisgaard, P.P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, et al.
Budesonide/formoterol combination as both maintenance and reliever medication in asthma.
Am J Respir Crit Care Med, 171 (2005), pp. 129-136
[79.]
C. Vogelmeier, A. D’Urzo, R. Pauwels, J.M. Merino, M. Jaspal, S. Boutet, et al.
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?.
Eur Respir J, 26 (2005), pp. 819-828
[80.]
K.F. Rabe, T. Atienza, P. Magyar, P. Larsson, C. Jorup, U. Lalloo.
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.
Lancet, 368 (2006), pp. 744-753
[81.]
L. Jayaram, M.M. Pizzichini, R.J. Cook, L.P. Boulet, C. Lemière, E. Pizzichini, et al.
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations.
Eur Respir J, 27 (2006), pp. 483-494
[82.]
C.G. Lofdahl, T.F. Reiss, J.A. Leff, E. Israel, M.J. Noonan, A.F. Finn, et al.
Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients.
BMJ, 319 (1999), pp. 87-90
[83.]
A. Deykin, M.E. Wechsler, H.A. Boushey, V.M. Chinchilli, S.J. Kunselman, T.J. Craig, et al.
Combination therapy with a long-acting b-agonist and a leukotriene antagonist in moderate asthma.
Am J Respir Crit Care Med, 175 (2007), pp. 228-234
[84.]
L. Bjermer, H. Bisgaard, J. Bousquet, L.M. Fabbri, A.P. Greening, T. Haahtela, et al.
Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial.
BMJ, 327 (2003), pp. 891
[85.]
M.J. Abramson, R.M. Puy, J.M. Weiner.
Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials.
Am J Respir Crit Care Med, 151 (1995), pp. 969-974
[86.]
O. Abadoglu, D. Mungan, G. Pasaoglu, G. Celik, Z. Misirligil.
Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations.
J Asthma, 41 (2004), pp. 279-283
[87.]
C. Christy, C.A. Aligne, P. Auinger, T. Pulcino, M. Weitzman.
Effectiveness of influenza vaccine for the prevention of asthma exacerbations.
Arch Dis Child, 89 (2004), pp. 734-735
[88.]
A. Sheikh, A. Alves, S. Dhami.
Pneumococcal vaccine for asthma.
Cochrane Database of Systematic Reviews, 1 (2002),
[89.]
P.G. Gibson, J. Coughlan, A.J. Wilson, M. Abramson, A. Bauman, M.J. Hensley, et al.
Self-management education and regular practitioner review for adults with asthma.
Cochrane Database Syst Rev, 62 (2000),
[90.]
J.P. Guevara, F.M. Wolf, C.M. Grum, N.M. Clark.
Effects of educational interventions for self management of asthma in children and adolescents: systematic review and meta-analysis.
BMJ, 326 (2003), pp. 1308-1319
[91.]
S.L. Janson, J.V. Fahy, J.K. Covington, S.M. Paul, W.M. Gold, H.A. Boushey.
Effects of individual self management education on clinical, biological, and adherence outcomes in asthma.
Am J Med, 115 (2003), pp. 620-626
[92.]
N.M. Clark, F. Nothwehr, M. Gong, D. Evans, L.A. Maiman, M.E. Hurwitz, et al.
Physician-patient partnership in managing chronic illness.
Acad Med, 70 (1995), pp. 957-960
[93.]
K.R. Chapman, L. Walker, S. Cluley, L. Fabbri.
Improving patient compliance with asthma therapy.
Respir Med, 94 (2000), pp. 2-9
[94.]
R.J. Adams, K. Boath, S. Homan, D.A. Campbell, R.E. Ruffin.
A randomized trial of peak-flow and symptom-based action plans in adults with moderate-to-severe asthma.
Respirology, 6 (2001), pp. 297-304
[95.]
R. Horne.
Compliance, adherence, and concordance: implications for asthma treatment.
Chest, 130 (2006), pp. S65-S72
[96.]
J. Douglass, R. Aaroni, D. Goeman, K. Stewart, S. Sawyer, F. Thien, et al.
A qualitative study of action plans for asthma.
BMJ, 324 (2002), pp. 1003-1005
[97.]
W.N. Hopman, N. Garvey, J. Olajos-Clow, A. White-Markham, M.D. Lougheed.
Outcomes of asthma education: results of a multisite evaluation.
Can Respir J, 11 (2004), pp. 291-297
[99.]
M.R. Partridge, S.R. Hill.
Enhancing care for people with asthma: the role of communication, education, training and self-management. 1998 World Asthma Meeting Education and Delivery of Care Working Group.
Eur Respir J, 16 (2000), pp. 333-348
[100.]
M.J. Abramson, M.J. Bailey, F.J. Couper, J.S. Driver, O.H. Drummer, A.B. Forbes, et al.
Are asthma medications and management related to deaths from asthma?.
Am J Respir Crit Care Med, 163 (2001), pp. 12-18
[101.]
J.R. Smith, M. Mugford, R. Holland, B. Candy, M.J. Noble, B.D. Harrison, et al.
A systematic review to examine the impact of psycho-educational interventions on health outcomes and costs in adults and children with difficult asthma.
Health Technol Assess, 9 (2005), pp. 1-182
[102.]
P.G. Gibson, H. Powell.
Written action plans for asthma: an evidence-based review of the key components.
Thorax, 59 (2004), pp. 94-99
[103.]
A.T. Ten Brinke, P.J. Sterk, A.A.M. Masclee, P. Spinhoven, J.T. Schimdt, A.H. Zwinderman, et al.
Risk factors of frequent exacerbations in difficult-to-treat asthma.
Eur Respir J, 26 (2005), pp. 812-818
[104.]
J. Serrano, V. Plaza, B. Sureda, J. De Pablo, C. Picado, S. Bardagi, et al.
Alexithymia: a relevant psychological variable in near-fatal asthma.
Eur Respir J, 28 (2006), pp. 296-302
[105.]
J. Côté, D.M. Bowie, P. Robichaud, J.G. Parent, L. Battisti, L.P. Boulet.
Evaluation of two different educational interventions for adult patients consulting with acute asthma exacerbation.
Am J Respir Crit Care Med, 63 (2001), pp. 1415-1419
[106.]
S.D. Edmond, C.R. Reed, L.G. Graff, S. Clark, C.A. Camargo.
Asthma education in the emergency department.
Ann Emerg Med, 36 (2000), pp. 2004-2011
[107.]
L.M. Osman, C. Calder, D.J. Godden, J.A. Friend, L. McKenzie, J.S. Legge, et al.
A randomised trial of self-management planning for adult patients admitted to hospital with acute asthma.
Thorax, 57 (2002), pp. 869-874
[108.]
C.L. Emerman, R. Cydulka.
Effect of pulmonary function test on the management of acute asthma.
Arch Intern Med, 155 (1995), pp. 2225-2228
[109.]
I. Dahlén, C. Janson.
Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease.
Chest, 122 (2002), pp. 1633-1637
[110.]
G.J. Rodrigo, C. Rodrigo, L.J. Nannini.
Asma fatal o casi fatal: ¿entidad clínica o manejo inadecuado?.
Arch Bronconeumol, 40 (2004), pp. 24-33
[111.]
W.O. Spitzer, S. Suissa, P. Ernst, R.I. Horwitz, B. Habbick, D. Cockcroft, et al.
The use of beta-agonist and the risk of death and near death from asthma.
N Engl J Med, 326 (1992), pp. 501-506
[112.]
P.M. Sturdy, C.R. Victor, H.R. Anderson, J.M. Bland, B.K. Butland, B.D. Harrison, et al.
Psychological, social and health behaviour risk factors for deaths certified as asthma: a national case-control study.
Thorax, 57 (2002), pp. 1034-1039
[113.]
C.C. Teerlink, M.J. Hegewald, L.A. Cannon-Albright.
A genealogical assessment of heritable predisposition to asthma mortality.
Am J Respir Crit Care Med, 176 (2007), pp. 865-870
[114.]
E.R. McFadden, R. Kisser, W.J. De Groot.
Acute bronchial asthma: relations between clinical and physiological manifestations.
N Engl J Med, 288 (1973), pp. 221-225
[115.]
R.M. Nowak, M.I. Pensier, D.D. Sarkar, J.A. Anderson, P.A. Kvale, A.E. Ortiz, et al.
Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma.
Ann Emerg Med, 11 (1982), pp. 64-69
[116.]
G. Rodrigo, C. Rodrigo.
Assessment of the patient with acute asthma in the emergency department. A factor analytic study.
Chest, 104 (1993), pp. 1325-1328
[117.]
R.A. Silverman, E. Flaster, P.L. Enright, S.G. Simonson.
FEV1 performance among patients with acute asthma. Results from a multicenter clinical trial.
Chest, 131 (2007), pp. 164-171
[118.]
M.G. Pearson, D.P. Spence, I. Ryland, B.D. Harrison.
Value of pulsus paradoxus in assessing acute severe asthma. British Thoracic Society Standards of Care Committee.
BMJ, 307 (1993), pp. 659
[119.]
G.D. Jay, K. Onuma, R. Davis, M.H. Chen, A. Mansell, D. Steele.
Analysis of physician ability in the measurement of pulsus paradoxus by sphygmomanometry.
Chest, 118 (2000), pp. 348-352
[120.]
M. Gill, S. Walker, A. Khan, S.M. Green, L. Kim, S. Gray, et al.
Exhaled nitric oxide levels during acute asthma exacerbation.
Acad Emerg Med, 12 (2005), pp. 579-586
[121.]
G. Rodrigo, C. Rodrigo.
A new index for early prediction of hospitalization in. patients with acute asthma.
Am J Emerg Med, 15 (1997), pp. 8-13
[122.]
C. Rodrigo, G. Rodrigo.
Therapeutic response patterns to high and cumulative doses of salbutamol in acute severe asthma.
Chest, 113 (1998), pp. 593-598
[123.]
G. Rodrigo, C. Rodrigo.
Early prediction of poor response in acute asthma patients in the emergency department.
Chest, 114 (1998), pp. 1016-1021
[124.]
M. McCarren, R.J. Zalenski, M. McDermott, K. Kaur.
Predicting recovery from acute asthma in an emergency diagnostic and treatment unit.
Acad Emerg Med, 7 (2000), pp. 28-35
[125.]
R.Y. Lin, D. Sauter, T. Newman, J. Sirleaf, J. Walters, M. Tavakol.
Continuous versus intermittent albuterol nebulization in the treatment of acute asthma.
Ann Emerg Med, 22 (1993), pp. 1847-1853
[126.]
G.S. Rudnitsky, R.S. Eberlein, J.M. Schoffstall, J.E. Mazur, W.H. Spivey.
Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department.
Ann Emerg Med, 22 (1993), pp. 1842-1846
[127.]
C. Reisner, A. Kotch, G. Dworkin.
Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study.
Ann Allergy Asthma Immunol, 75 (1995), pp. 41-47
[128.]
M.B. Dolovich, R.C. Ahrens, D.R. Hess, P. Anderson, R. Dhand, J.L. Rau, et al.
Device selection and outcomes of aerosol therapy: evidence-based guidelines.
Chest, 127 (2005), pp. 335-371
[129.]
C.J. Cates, J.A. Crilly, B.H. Rowe.
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma.
Cochrane Database of Systematic Reviews, 2 (2006),
[130.]
B.H. Rowe, C. Spooner, F.M. Ducharme, J.A. Bretzlaff, G.W. Bota.
Early emergency department treatment of acute asthma with systemic corticosteroids.
Cochrane Database of Systematic Reviews, (2001),
[131.]
J. Kolbe, W. Fergusson, J. Garret.
Rapid onset asthma: a severe but uncommon manifestation.
Thorax, 53 (1998), pp. 241-247
[132.]
J.W. Chien, R. Ciufo, R. Novak, M. Skowronski, J. Nelson, A. Coreno, et al.
Uncontrolled oxygen administration and respiratory failure in acute asthma.
Chest, 117 (2000), pp. 728-733
[133.]
G.J. Rodrigo, M. Rodríguez-Verde, V. Peregalli, C. Rodrigo.
Effects of short-term 28% and 100% oxygen in PaCO2 and peak expiratory flow rate in acute asthma. A randomized trial.
Chest, 124 (2003), pp. 1312-1317
[134.]
L. Strauss, R. Hejal, G. Galan, L. Dixon, E.R. McFadden.
Observations of the effects of aerosolized albuterol in acute asthma.
Am J Respir Crit Care Med, 155 (1997), pp. 545-548
[135.]
A. Travers, A.P. Jones, K. Kelly, S.J. Barker, C.A. Camargo, B.H. Rowe.
Intravenous beta2-agonists for acute asthma in the emergency department.
Cochrane Database of Systematic Reviews, 1 (2001),
[136.]
K.B. Newman, S. Milne, C. Hamilton, K. Hall.
A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma.
Chest, 121 (2002), pp. 1036-1041
[137.]
M.H. Osmond, M. Gazarian, R.L. Henry, T.J. Clifford.
Barriers to metered-dose inhaler/spacer use in Canadian pediatric emergency departments: a national survey.
Acad Emerg Med, 14 (2007), pp. 1106-1113
[138.]
K.F. Hurley, J. Sargeant, J. Duffy, I. Sketris, D. Sinclair, J. Ducharme.
Perceptual reasons for resistance to change in the emergency department use of holding chambers for children with asthma.
Ann Emerg Med, 51 (2008), pp. 70-77
[140.]
Camargo CA, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists for acute asthma. Cochrane Database of Systematic Reviews. 2003b;4:CD001115. DOI: 10.1002/14651858.CD001115.
[141.]
G.J. Rodrigo, H. Neffen, F.D. Colodenco, J.A. Castro-Rodriguez.
Formoterol for acute asthma in the emergency department: A systematic review with meta-analysis.
Ann Allergy Asthma Immunol, 104 (2010), pp. 247-252
[142.]
R. Nowak, C.H. Emerman, J.P. Hanrahanc, M.V. Parsey, N.A. Hanania, R. Claus, et al.
A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults.
Am J Emerg Med, 24 (2006), pp. 259-267
[143.]
G.J. Rodrigo, L.J. Nannini.
Comparison between nebulized adrenaline and beta2 agonists for the treatment of acute asthma. A meta-analysis of randomized trials.
Am J Emerg Med, 24 (2006), pp. 217-222
[144.]
G.J. Rodrigo, J.A. Castro-Rodríguez.
Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis.
Thorax, 60 (2005), pp. 740-746
[145.]
G. Rodrigo, C. Rodrigo.
Corticosteroids in the Emergency Department therapy of acute adult asthma. An evidence-based evaluation.
Chest, 116 (1999), pp. 285-295
[146.]
B.H. Rowe, C.H. Spooner, F.M. Ducharme, G.W. Bota.
Corticosteroids for preventing relapse following acute exacerbations of asthma.
Cochrane Database of Systematic Reviews, 3 (2007),
[147.]
F.A. Lederle, R.E. Pluhar, A.M. Joseph, D.E. Niewoehner.
Tapering of corticosteroid therapy following exacerbation of asthma. A randomized, double-blind, placebo-controlled trial.
Arch Intern Med, 147 (1987), pp. 2201-2203
[148.]
B.R. O’Driscoll, S. Kalra, C.A.C. Pickering, K.B. Carroll, A.A. Woodcock, M. Wilson.
Double-blind trial of steroid tapering in acute asthma.
Lancet, 341 (1993), pp. 324-327
[149.]
M.Q. Hatton, A.S. Vathenen, M.J. Allen, S. Davies, N.J. Cooke.
A comparison of “abruptly stopping” with “tailing off” oral corticosteroids in acute asthma.
Respir Med, 89 (1995), pp. 101-104
[150.]
G.J. Rodrigo.
Rapid effects of inhaled corticosteroids in acute asthma. An evidence-based evaluation.
Chest, 130 (2006), pp. 1301-1311
[151.]
B.H. Rowe, J.A. Bretzlaff, C. Bourdon, G.W. Bota, C.A. Camargo.
Magnesium sulfate for treating exacerbations of acute asthma in the emergency department.
Cochrane Database of Systematic Reviews, 1 (2000),
[152.]
R.A. Silverman, H. Osborn, J. Runge, E.J. Gallagher, W. Chiang, J. Feldman, et al.
IV magnesium sulfate in the treatment of acute severe asthma. A multicenter randomized controlled trial.
Chest, 122 (2002), pp. 489-497
[153.]
M. Blitz, S. Blitz, R. Beasely, B.M. Diner, R. Hughes, J.A. Knopp, et al.
Inhaled magnesium sulphate in the treatment of acute asthma.
Cochrane Database of Systematic Reviews, 4 (2005),
[154.]
G.J. Rodrigo, L.J. Nannini.
Is there a place for nebulized magnesium sulfate in the treatment of acute asthma? A systematic review.
Curr Ther, 1 (2006), pp. 181-185
[155.]
K. Parameswaran, J. Belda, B.H. Rowe.
Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma.
Cochrane Database of Systematic Reviews, 4 (2000),
[156.]
G. Rodrigo, C. Pollack, C. Rodrigo, B.H. Rowe.
Heliox for nonintubated acute asthma patients.
Cochrane Database of Systematic Reviews, 4 (2006), pp. CD002884
[157.]
C.A. Camargo, H.A. Smithline, M.O. Malice, S.A. Green, T.F. Reiss.
Randomized controlled trial of intravenous montelukast in acute asthma.
Am J Respir Crit Care Med, 167 (2003), pp. 528-533
[158.]
A.C. Cylly, A. Kara, T. Ozdemir, C. Ogus, K.H. Gulkesen.
Effects of oral montelukast on airway function in acute asthma.
Respir Med, 97 (2003), pp. 533-536
[159.]
S.L. Johnston, F. Blasi, P.N. Black, R.J. Martin, D.J. Farrel, R.B. Nieman.
The effect of telithromycin in acute exacerbations of asthma.
N Engl J Med, 354 (2006), pp. 1589-1600
[160.]
K.S. Joseph, L. Blais, P. Ernst, S. Suissa.
Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquillisers.
BMJ, 312 (1996), pp. 79-82
[161.]
A. Soroksky, D. Stav, I. Shpirer.
A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack.
Chest, 123 (2003), pp. 1018-1025
[162.]
A. Grunfeld, J.M. Fitzgerald.
Discharge considerations in acute asthma.
Can Respir J, 3 (1996), pp. 322-324
[163.]
R. Darioli, C. Perret.
Mechanical controlled hypoventilation in status asthmaticus.
Am Rev Respir Dis, 129 (1984), pp. 385-387
[164.]
D.V. Tuxen.
Permissive hypercapnic ventilation.
Am J Respir Crit Care Med, 150 (1994), pp. 870-874
[165.]
J.A. Castro-Rodríguez, C.J. Holberg, A.L. Wright, F.D. Martínez.
A clinical index to define risk of asthma in young children with recurrent wheezing.
Am J Respir Crit Care Med, 162 (2000), pp. 1403-1406
[166.]
S.V. Mehta, P.C. Parkin, D. Stephens, K.A. Keogh, S. Schuh.
Oxygen saturation as a predictor of prolonged, frequent bronchodilator therapy in children with acute asthma.
J Pediatr, 145 (2004), pp. 641-645
[167.]
K.A. Keogh, C. Macarthur, P.C. Parkin, D. Stephens, R. Arseneault, O. Tennis, et al.
Predictors of hospitalization in children with acute asthma.
J Pediatr, 139 (2001), pp. 273-277
[168.]
D. Pavón, J.A. Castro-Rodríguez, L. Rubilar, G. Girardi.
Relation between pulse oximetry and clinical score in children with acute wheezing less than 24 months of age.
Pediatr Pulmonol, 27 (1999), pp. 423-427
[169.]
J.A. Castro-Rodríguez, G.J. Rodrigo.
Beta-agonists through metered-dose inhaler with valved holding chamber versus nebulizer for acute exacerbation of wheezing or asthma in children under 5 years of age: a systematic review with meta-analysis.
J Pediatr, 145 (2004), pp. 172-177
[170.]
J.C. Carl, T.R. Myers, H.L. Kirchner, C.M. Kercsmar.
Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.
J Pediatr, 143 (2003), pp. 731-736
[171.]
R.J. Scarfone, S.M. Fuchs, A.L. Nager, S.A. Shane.
Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma.
Pediatrics, 92 (1993), pp. 513-583
[172.]
D.M. Gries, D.R. Moffitt, E. Pulos, E.R. Carter.
A single dose of intramuscularly administered dexamethasone acetate is as effective as oral prednisone to treat asthma exacerbations in young children.
J Pediatr, 136 (2000), pp. 298-303
[173.]
A. Mitra, D. Bassler, K. Watts, T.J. Lasserson, F.M. Ducharme.
Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators.
Cochrane Database of Systematic Reviews, 2 (2005),
[174.]
S.R. Smith, B.H. Baty, D. Hodge.
Validation of the pulmonary score. An asthma severity score for children.
Acad Emerg Med, 9 (2002), pp. 99-104
[175.]
M.S. Rhanana, R.P. Geilen, S. Singui, M. Van der Akker, N.H. Chavannes.
Which clinical signs and symptoms predict hypoxemia in acute childhood asthma?.
Indian J Pediatr, 73 (2006), pp. 771-775
[176.]
W. Carroll, W. Lenney.
Drug therapy in the management of acute asthma.
Arch Dis Child Educ Pract Ed, 92 (2007), pp. 82-86
[177.]
F. Qureshi, A. Zaritsky, C. Welch, T. Meadows, B.L. Burke.
Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma.
Ann Emerg Med, 46 (2005), pp. 29-36
[178.]
M.E. Ralston, M.S. Euwema, K.R. Knecht.
Comparison of levalbuterol and racemic albuterol combined with ipratropium bromide in acute pediatric asthma: a randomized controlled trial.
J Emerg Med, 29 (2005), pp. 29-35
[179.]
J.M. Becker, A. Aroraq, R.J. Scarfone, N.D. Spector, M.E. Fontana-Penn, E. Gracely.
Oral versus intravenous corticosteroids in children hospitalized with asthma.
J Allergy Clin Immunol, 103 (1999), pp. 586-590
[180.]
T.A. Bradshaw, S.P. Matusiewicz, G.K. Crompton, J.A. Innes, A.P. Greening.
Intravenous magnesium sulphate provides no additive benefit to standard management in acute asthma.
Respir Med, 102 (2008), pp. 143-149
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
